Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - letrozole - film coated tablet - 2.5 milligram - letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - letrozole - film coated tablet - 2.5 milligram - letrozole

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies (14.2, 14.3)] . letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see clinical studies (14.4, 14.5)]. - pregnancy: letrozole can cause fetal harm [see use in specific populations (8.1)] . - known hyper

Israel - English - Ministry of Health

dexcel ltd, israel - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - letrozole - dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. letrozole - dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole